Ballew Advisors’s Achieve Life Sciences ACHV Stock Holding History

Ballew Advisors’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-30	Closed	-$1K	–	95
2018 Q3	$1K	Buy	+30	New	+$1.9K	﹤0.01%	419

Other funds holding ACHV

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Ballew Advisors's ACHV Position: Q4 2018 in Review

Ballew Advisors sold out of Achieve Life Sciences (ACHV) in Q4 2018, closing a stake of 30 shares — an estimated $1K sold.

Ballew Advisors first reported a position in ACHV in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 11 funds tracked by Wall St. Rank hold ACHV as of Q4 2018.

Ballew Advisors reported no remaining Achieve Life Sciences position as of Q4 2018 after selling out during the quarter.
Ballew Advisors sold 30 Achieve Life Sciences shares in Q4 2018, an estimated $1K.
Ballew Advisors first reported a position in Achieve Life Sciences in Q3 2018 and held it in 1 quarter.
Ballew Advisors's Achieve Life Sciences position peaked at $1K in Q3 2018.
11 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.